Analysts Set Collegium Pharmaceutical, Inc. (NASDAQ:COLL) PT at $43.60

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has earned an average rating of “Moderate Buy” from the five brokerages that are covering the stock, Marketbeat reports. One analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $43.60.

Several research analysts have recently issued reports on the company. Needham & Company LLC raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price target for the company in a research note on Friday, January 10th. Piper Sandler decreased their target price on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research report on Tuesday, February 4th. Finally, HC Wainwright reissued a “buy” rating and set a $50.00 target price on shares of Collegium Pharmaceutical in a research note on Monday, March 24th.

Collegium Pharmaceutical Stock Up 0.5 %

Shares of NASDAQ:COLL opened at $29.85 on Friday. The company’s fifty day moving average is $30.29 and its two-hundred day moving average is $32.35. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. Collegium Pharmaceutical has a 1-year low of $27.28 and a 1-year high of $42.29. The stock has a market capitalization of $939.86 million, a price-to-earnings ratio of 12.87 and a beta of 0.99.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The company had revenue of $181.95 million during the quarter, compared to the consensus estimate of $179.68 million. Equities analysts anticipate that Collegium Pharmaceutical will post 5.62 EPS for the current year.

Insider Buying and Selling at Collegium Pharmaceutical

In related news, CFO Colleen Tupper sold 10,445 shares of the company’s stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $30.01, for a total transaction of $313,454.45. Following the transaction, the chief financial officer now directly owns 165,246 shares of the company’s stock, valued at approximately $4,959,032.46. The trade was a 5.95 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of the stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total value of $1,123,200.00. Following the completion of the sale, the executive vice president now directly owns 154,204 shares of the company’s stock, valued at approximately $4,330,048.32. This represents a 20.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 109,193 shares of company stock valued at $3,243,594. 3.98% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Collegium Pharmaceutical

A number of large investors have recently made changes to their positions in COLL. Nisa Investment Advisors LLC grew its stake in Collegium Pharmaceutical by 14.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock valued at $71,000 after purchasing an additional 316 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Collegium Pharmaceutical by 1.9% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,221 shares of the specialty pharmaceutical company’s stock valued at $522,000 after buying an additional 339 shares during the last quarter. AlphaQuest LLC grew its stake in shares of Collegium Pharmaceutical by 3.0% in the 4th quarter. AlphaQuest LLC now owns 12,780 shares of the specialty pharmaceutical company’s stock valued at $366,000 after buying an additional 374 shares in the last quarter. Foundry Partners LLC increased its holdings in Collegium Pharmaceutical by 2.4% in the fourth quarter. Foundry Partners LLC now owns 16,162 shares of the specialty pharmaceutical company’s stock worth $463,000 after buying an additional 381 shares during the last quarter. Finally, Gallacher Capital Management LLC increased its holdings in Collegium Pharmaceutical by 3.3% in the fourth quarter. Gallacher Capital Management LLC now owns 14,571 shares of the specialty pharmaceutical company’s stock worth $417,000 after buying an additional 470 shares during the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.